Final Results part 3 of 3

RNS Number : 1710A

AstraZeneca PLC

27 January 2011

 



AstraZeneca Development Pipeline

27 January 2011

Line Extensions

Compound	Mechanism	Area Under Investigation	Phase	Estimated Filing
				US	EU	Japan	Emerging
Cardiovascular
Kombiglyze XR/ Onglyza/ metformin IR FDC #*	DPP-4 inhibitor + metformin FDC	diabetes	III	Launched	Filed		Filed
Dapagliflozin/ metformin FDC#	SGLT2 inhibitor + metformin FDC	diabetes	III	1H 2012	1H 2012
Onglyza SAVOR#	DPP-4 inhibitor	outcomes study	III	2016
Brilinta PEGASUS-TIMI	ADP receptor antagonist	outcomes study	III	2014	2014	2014	2014
Crestor	statin	outcomes in subjects with elevated CRP	III	Launched	Launched	TBC	Filed
Axanum	proton pump inhibitor + low dose aspirin FDC	low dose aspirin associated peptic ulcer	III	Filed***	Filed	2014	Filed
Gastrointestinal
Nexium	proton pump inhibitor	peptic ulcer bleeding	III	Filed	Launched
Nexium	proton pump inhibitor	GERD	III	Launched	Launched	Filed	Launched
Neuroscience
Seroquel XR	D2/5HT2 antagonist	major depressive disorder	III	Launched**	Launched**		Launched
Diprivan#	sedative and anaesthetic	conscious sedation	III		Launched	2H 2012	Launched
EMLA#	local anaesthetic	topical anaesthesia	III		Launched	Filed	Launched
Oncology
Iressa	EGFR tyrosine kinase inhibitor	1st line EGFR mut+ NSCLC	III		Launched	Filed	Launched
Faslodex	oestrogen receptor antagonist	high dose (500mg) 2nd line advanced breast cancer	III	Launched	Launched	Filed	Filed
Infection
FluMist/Fluenz	live, attenuated, intranasal influenza virus vaccine	influenza	III	Launched	Filed
Respiratory & Inflammation
Oxis	long-acting β2 agonist	COPD	III		Launched	3Q 2011
Symbicort	inhaled steroid/ long-acting β2 agonist	COPD	III	Launched	Launched	4Q 2011	Launched
Symbicort	inhaled steroid/ long-acting β2 agonist	SMART	III		Launched	3Q 2011	Launched

^#Partnered product

* Kombiglyze XR US; Onglyza/metformin IR FDC EU

**Adjunct only, monotherapy withdrawn

***CRL Received

NCEs

Phase III/Registration

Compound	Mechanism	Area Under Investigation	Phase	Estimated Filing
				US	EU	Japan	Emerging
Cardiovascular
Brilinta/Brilique	ADP receptor antagonist	arterial thrombosis	III	Filed*	Launched	2013	Approved
Dapagliflozin#	SGLT2 inhibitor	diabetes	III	Filed	Filed	2013	2Q 2011
Neuroscience
Vimovo#	naproxen + esomeprazole	signs and symptoms of OA, RA and AS	III	Launched	Launched		Filed
TC-5214#	neuronal nicotinic receptor modulator	major depressive disorder (adjunct)	III	2H 2012	2015
Oncology
Vandetanib (Zactima)	VEGFR/EGFR tyrosine kinase inhibitor with RET kinase activity	medullary thyroid cancer	III	Filed	Filed	3Q 2011	3Q 2011
Zibotentan	endothelin A receptor antagonist	castrate resistant prostate cancer	III	1H 2012	1H 2012		1H 2012
Infection
MEDI-3250	live, attenuated, intranasal influenza virus vaccine  (quadrivalent)	seasonal influenza	III	1H 2011	TBD
Zinforo# (ceftaroline)	extended spectrum cephalosporin with affinity to penicillin- binding proteins	pneumonia /skin infections	III		Filed		3Q 2011
Respiratory & Inflammation
Fostamatinib #	spleen tyrosine kinase (SYK) inhibitor	rheumatoid arthritis	III	2013	2013		2013

^#Partnered product

*CRL received

NCEs

Phases I and II

Compound		Mechanism	Area Under Investigation	Phase	Estimated Filing
					US	EU	Japan	Emerging
Cardiovascular
AZD1656		GK activator	diabetes	II
AZD6714		GK activator	diabetes	I
AZD8329		11BHSD inhibitor	diabetes/obesity	I
AZD7687		diacylglycerol acyl transferase -1 inhibitor	diabetes/obesity	I
AZD5658		GK activator	diabetes/obesity	I
AZD4017		11BHSD inhibitor	glaucoma	I
Neuroscience
AZD3480#	alpha4/beta2 neuronal nicotinic receptor agonist		ADHD	II
AZD6765	NMDA receptor antagonist		major depressive disorder	II	2016	2016
AZD2066	metabotropic glutamate receptor 5 antagonist		chronic neuropathic pain	II
AZD2066	metabotropic glutamate receptor 5 antagonist		major depressive disorder	II
NKTR-118#	oral peripherally-acting opioid antagonist		opioid-induced constipation	II	2013	2013
TC-5214#	neuronal nicotinic receptor modulator		major depressive disorder (monotherapy)	II
TC-5619#	alpha7 neuronal nicotinic receptor agonist		cognitive disorders in schizophrenia	II
AZD1446#	alpha4/beta2 neuronal nicotinic receptor agonist		Alzheimer's disease/ADHD	II
AZD2423	chemokine antagonist		chronic neuropathic pain	II
AZD3241	myeloperoxidase (MPO) inhibitor		Parkinson's disease	I
AZD3043#	GABA-A receptor modulator		short acting sedative/ anaesthetic	I
MEDI-578	anti-NGF MAb		OA pain	I
AZD5213	H3AN		Alzheimer's disease/ADHD	I

^#Partnered product

NCEs

Phases I and II (continued)

Compound	Mechanism	Area Under Investigation	Phase	Estimated Filing
				US	EU	Japan	Emerging
Oncology
Recentin	VEGFR tyrosine kinase inhibitor	NSCLC	II	2016	2016
Selumetinib# (AZD6244) (ARRY-142886)	MEK inhibitor	solid tumours	II	2015	2015
Olaparib	PARP inhibitor	serous ovarian cancer	II	2015	2015	2016	2016
AZD1152	aurora kinase inhibitor	haematological malignancies	II
AZD8931	erbB kinase inhibitor	breast cancer chemo combi/solid tumours	II	2015	2015
MEDI-575#	anti-PDGFR-alpha mAb	solid tumours	II
AZD2461	PARP inhibitor	solid tumours	I
AZD3514	androgen receptor downregulator	prostate cancer	I
AZD7762	CHK1 kinase inhibitor	solid tumours	I
AZD8330# (ARRY 424704)	MEK inhibitor	solid tumours	I
CAT-8015	anti-CD22 recombinant immunotoxin	haematological malignancies	I
MEDI-551	anti-CD19 MAb	haematological malignancies	I
AZD8055	TOR kinase inhibitor	range of tumours	I
MEDI-573#	anti-IGF MAb	solid tumours	I
AZD1480	JAK2 inhibitor	myeloproliferative diseases/solid tumours	I
AZD4547	FGFR tyrosine kinase inhibitor	solid tumours	I
AZD2014	TOR kinase inhibitor	solid tumours	I
Selumetinib (AZD6244)  (ARRY-142886) /MK2206#	MEK/AKT inhibitor	solid tumours	I
MEDI-3617	anti-ANG-2 MAb	solid tumours	I
AZD5363	AKT inhibitor	solid tumours	I
MEDI-565	anti-CEA BiTE	solid tumours	I
Infection
AZD9773 #	anti-TNF-alpha polyclonal antibody	severe sepsis	II	2015	2015	2015	2015
CAZ104#	beta lactamase inhibitor/cephalosporin	serious infections	II		2013		2014
Motavizumab#	humanized MAb binding to RSV F protein	early and late treatment of RSV in paeds >1 yr	II
CXL104# (CEF104)	beta lactamase inhibitor/cephalosporin	MRSA	II		2015
MEDI-534	RSV/PIV-3 vaccine	RSV/PIV prophylaxis	I
MEDI-550	pandemic influenza virus vaccine	pandemic influenza prophylaxis	I
MEDI-559	RSV vaccine	RSV prophylaxis	I
AZD5847	oxazolidinone antibacterial inhibitor	tuberculosis	I
AZD9742	BTGT4 IV	MRSA	I

^#Partnered product

NCEs

Phases I and II (continued)

Compound	Mechanism	Area Under Investigation	Phase	Estimated Filing
				US	EU	Japan	Emerging
Respiratory & Inflammation
AZD1981	CRTh2 receptor antagonist	asthma/COPD	II
MEDI-528#	anti-IL-9 MAb	asthma	II
CAT-354	anti-IL-13 MAb	asthma	II
AZD3199	iLABA	asthma/COPD	II
MEDI-563#	anti-IL-5R MAb	asthma	II
MEDI-545#	anti-IFN-alpha MAb	SLE, myositis	II
AZD8848	Toll like receptor 7 agonist	asthma	II
CAM-3001#	anti-GM-CSFR MAb	rheumatoid arthritis	II
AZD2423	CCR2b antagonist	COPD	II
AZD8683	muscarinic antagonist	COPD	II
AZD5423	inhaled SEGRA	COPD	II
AZD5069	CXCR2	COPD	II
AZD9819	neutrophil elastase inhibitor	COPD	I
MEDI-546#	anti-IFNalphaR MAb	scleroderma	I
MEDI-551	anti-CD19 MAb	scleroderma	I
MEDI-570#	anti-ICOS MAb	SLE	I
MEDI-557	RSV MAb - extended half-life	COPD	I

^#Partnered product

Development Pipeline - Discontinued Projects vs 29 July 2010

Cardiovascular/Gastrointestinal

NCE/Line Extension	Compound	Area Under Investigation
NCE	AZD6370	diabetes
NCE	Lesogaberan (AZD3355)	GERD
NCE	AZD1386	GERD
NCE	AZD2066	GERD
NCE	AZD2516	GERD
NCE	AZD4017	diabetes/obesity
NCE	Certriad	dyslipidaemia

Neuroscience

NCE/Line Extension	Compound	Area Under Investigation
NCE	AZD8529	schizophrenia
NCE	AZD7268	depression/anxiety
NCE	AZD2327	depression/anxiety
NCE	AZD2516	chronic neuropathic pain
LCM	Seroquel XR	generalised anxiety disorder US

Oncology

NCE/Line Extension	Compound	Area Under Investigation
NCE	AZD4769	solid tumours
LCM	Faslodex	1st line advanced breast cancer
NCE	Olaparib	gBRCA breast
NCE	MEDI-547	solid tumours

Infection

NCE/Line Extension	Compound	Area Under Investigation
NCE	AZD7295	Hepatitis C
NCE	Motavizumab	RSV prevention
NCE	MEDI-560	PIV prophylaxis

Respiratory & Inflammation

NCE/Line Extension	Compound	Area Under Investigation
NCE	AZD6553	COPD
NCE	AZD9668	COPD

Comments

As disclosure of compound information is balanced by the business need to maintain confidentiality, information in relation to some compounds listed here has not been disclosed at this time.

Compounds in development are displayed by phase.

 

END

 

 

FR BRMFTMBTTMIB